Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08HKT
|
|||
| Former ID |
DIB008616
|
|||
| Drug Name |
BEMORADAN
|
|||
| Synonyms |
Orf-22867; RWJ-22867; Bemoradan; Rac-7-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)-2H-1,4-benzoxazin-3(4H)-one; Rac-5-Methyl-6-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)-2,3,4,5-tetrahydropyridazin-3-one
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Heart failure [ICD-11: BD10-BD13; ICD-10: I50, I50.9; ICD-9: 428] | Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H13N3O3
|
|||
| Canonical SMILES |
CC1CC(=O)NN=C1C2=CC3=C(C=C2)NC(=O)CO3
|
|||
| InChI |
1S/C13H13N3O3/c1-7-4-11(17)15-16-13(7)8-2-3-9-10(5-8)19-6-12(18)14-9/h2-3,5,7H,4,6H2,1H3,(H,14,18)(H,15,17)
|
|||
| InChIKey |
XZPGINPFWXLYNW-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 112018-01-6
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phosphodiesterase 3A (PDE3A) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Purine metabolism | |||
| cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | ||||
| Morphine addiction | ||||
| Reactome | cGMP effects | |||
| G alpha (s) signalling events | ||||
| WikiPathways | miR-targeted genes in muscle cell - TarBase | |||
| miR-targeted genes in lymphocytes - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Evaluation of the excretion, and metabolism of the cardiotonic agent bemoradan in male rats and female beagle dogs. Eur J Drug Metab Pharmacokinet. 2001 Oct-Dec;26(4):263-71. | |||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.